JXR(01951) suggests launching an asset-backed securities program on the Shanghai Stock Exchange.
Jin Xin Reproductive (01951) announced that the company is considering launching an asset-backed securities (ABS) program involving the issuance of a single category of securities (ABS) based on the related assets of its subsidiary, Shenzhen Hengyu Lianxiang Investment Development Co., Ltd. (Hengyu). These related assets mainly include real estate buildings currently held by Hengyu, located in the Futian District of Shenzhen, China, currently occupied by the group's Shenzhen Zhongshan Hospital. According to the plan, ABS will be traded on the Shanghai Stock Exchange (proposed trading). If the proposed transaction is successfully completed, it is expected to significantly reduce the company's existing leverage ratio and optimize its capital structure and asset quality.
JXR (01951) Announcement: The company is considering launching an asset-backed securities plan (ABS plan), involving the issuance of a single category of securities (ABS) based on the related assets of its subsidiary Shenzhen Hengyu Lianxiang Investment and Development Co., Ltd. (Hengyu). These related assets primarily include the real estate buildings currently owned by Hengyu, located in the Futian District of Shenzhen, China, currently occupied by the Group's Shenzhen Zhongshan Hospital. According to the plan, the ABS will be traded on the Shanghai Stock Exchange (proposed trading). If the proposed trading goes smoothly, it is expected to significantly reduce the company's existing leverage ratio and optimize its capital structure and asset quality.
If the company proceeds with the proposed trading, according to Rule 14.29 of the Stock Exchange of Hong Kong Limited Securities Listing Rules (Listing Rules), the transaction may be deemed as a sale of Hengyu. The company will timely apply for relevant approvals from regulatory authorities (including but not limited to the China Securities Regulatory Commission, Shanghai Stock Exchange, and Stock Exchange of Hong Kong Limited) regarding the proposed trading.
As of the date of this announcement, the details and terms of the proposed trading have not been finalized.
Related Articles

SAINT BELLA GP (02508) to spend about 22.4 million yuan to acquire a minority stake in the maternity center business under Freya.

EPIWORLD (02726): Zhao Jianhui elected as Chairman of the Board.

KNOWLEDGE ATLAS (02513): Xu Wenming appointed as independent non-executive director.
SAINT BELLA GP (02508) to spend about 22.4 million yuan to acquire a minority stake in the maternity center business under Freya.

EPIWORLD (02726): Zhao Jianhui elected as Chairman of the Board.

KNOWLEDGE ATLAS (02513): Xu Wenming appointed as independent non-executive director.

RECOMMEND





